Kiniksa Pharmaceuticals reported net product revenue of $180.9 million for its flagship drug ARCALYST in the third quarter ended September 30 2025, a 61 % year‑over‑year increase that reflects growing adoption of the therapy for recurrent pericarditis.
The company posted a net income of $18.4 million for the quarter, with basic earnings per share of $0.25 and diluted earnings per share of $0.23. The diluted EPS fell short of the consensus estimate of $0.33.
Kiniksa raised its full‑year 2025 ARCALYST net sales guidance to a range of $670 million to $675 million, up from the previously announced $625 million to $640 million, citing stronger market penetration and longer average therapy duration.
The monoclonal antibody candidate KPL‑387 received orphan drug designation from the FDA in October 2025, positioning the asset for accelerated development and potential market exclusivity.
Cash and short‑term investments stood at $352.1 million as of September 30 2025, an increase of $44.3 million from the prior quarter, providing additional liquidity for commercial expansion and pipeline progress.
Additional context: the average total duration of ARCALYST therapy in recurrent pericarditis increased to approximately 32 months by the end of Q3 2025, up from 27 months at the end of 2024, and 3,825 prescribers have written ARCALYST prescriptions for recurrent pericarditis since launch.
Future milestones for KPL‑387 include the release of Phase 2/3 dose‑focusing data in the second half of 2026, which will inform the next steps in development.
Kiniksa expects its current operating plan to remain cash‑flow positive on an annual basis.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.